NCT05549947View on ClinicalTrials.gov

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

October 8, 2022

Primary Completion Date

September 15, 2023

Study Completion Date

November 23, 2023

Conditions
Moderate to Severe Atopic Dermatitis
Interventions
DRUG

SHR1819

Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，

DRUG

Placebo

Treatment group D：placebo

Trial Locations (1)

200040

Huashan Sub-Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY